Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AbundRX vs Spry

AbundRX
Graded #193

Higher grade

vs+9.5
Spry
Graded #409

Lower grade

The verdict

AbundRX takes it — 66.3/100 to 56.8/100.

AbundRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. AbundRX (Abundant Wellness) is an online medical weight-care platform connecting patients with licensed clinicians for compounded GLP-1 treatment.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAbundRX +12
66
54
Dose & formulationEven
64
64
Clinical oversightAbundRX +24
79
55
Labs & monitoringAbundRX +1
53
52
FulfillmentAbundRX +13
74
61
Contract termsEven
55
55
AbundRX · left barSpry · right bar

The numbers

MetricAbundRXSpry
WeighScore66.3/10056.8/100
GradeCC
Scorecard rank#193#409
Semaglutide$179/mo (compounded)$199/mo (starting dose, compounded)
Tirzepatide$279/mo (compounded)$299/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
AbundRX

Graded #193 · C

Strengths

  • Two clear compounded GLP-1 pathways with transparent pricing — semaglutide $179/mo and tirzepatide $279/mo
  • Fast, free shipping and a simple few-minute online health assessment
  • Provider-guided care connecting patients with licensed US clinicians
  • Publishes Terms, Privacy, and Refund policies

Where it loses points

  • Claims LegitScript certification in text but displays no verifiable seal or listing
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Compounding pharmacy not named; no HIPAA notice found; state availability not published
  • Heavily hedged marketing language ('may include', 'helping connect patients') — reads like a lead-generation platform
Spry

Graded #409 · C

Strengths

  • Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
  • Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
  • Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
  • No contracts or commitment required
  • LegitScript Certified with a public verification link

Where it loses points

  • Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
  • Intake reviewed by a nurse practitioner, not an MD
  • States served not disclosed publicly
  • Pharmacy partner not named, and 503A vs 503B designation not specified
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard